The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630, China
NCT Number: NCT03590886
To compare intestinal flora diversity in different PBC patients with UDCA responses, and further study the differences of bile acid metabolism and short chain fatty acid metabolism in feces and serum of two groups of PBC patients.
Looking for future studies?
Notify Me30 year–70 year
All sexes
Observational
Guangzhou, Guangdong, 510630, China
The PBC patients have been enrolled in the study for UDCA treatment more than 1 year, who is divided into the UDCA total response Group and the other poor response group according to Paris-I/II standard .The feces of two groups of patients were collected and the differences of microbial polymorphism of fecal microorganism in two groups were observed. The metabolic differences of bile acids and short chain fatty acids in serum and feces of two groups of PBC patients were studied by means of metabolic proteomics.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
1.Confirmed diagnostic criteria about PBC, and orally UDCA treatment for more than a year; 2.30-70 years old; 3.Currently only UDCA therapy, not glucocorticoids and immunosuppressor treatment.
Exclusion criteria
biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
Other names: poor response group
Time frame: 6 months
Macrogenomic examination of fecal microbial DNA
Time frame: 6 months
The examination of bile acid metabolites by ELISA methods
Time frame: 6 months
The examination of short chain fatty metabolites by ELISA methods
Sun Yat-sen University
Other
A Clinical Study About Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03743272
Autoimmune Diseases, Autoimmune Hepatitis
Leiden, Netherlands
View Trial DetailsNCT01161953
Bile Duct Diseases, Biliary Tract Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT02846896
Bile Duct Diseases, Biliary Tract Diseases
Lugano, Switzerland
View Trial DetailsNCT03112681
Bile Duct Diseases, Biliary Tract Diseases
Pasadena, California, United States
View Trial Details